Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $1,054,130.00 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 77,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the sale, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $955,945.32. This trade represents a 52.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $13.24 on Monday. Oric Pharmaceuticals, Inc. has a fifty-two week low of $7.23 and a fifty-two week high of $14.93. The stock has a market cap of $1.37 billion, a PE ratio of -9.81 and a beta of 1.02. The stock has a fifty day moving average of $11.85 and a 200-day moving average of $10.73.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). On average, sell-side analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on ORIC shares. HC Wainwright raised their price objective on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Stifel Nicolaus started coverage on shares of Oric Pharmaceuticals in a report on Friday, June 12th. They set a “buy” rating and a $14.00 target price on the stock. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Friday, May 15th. Benchmark reissued a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Friday, July 17th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.45.

Institutional Trading of Oric Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Oric Pharmaceuticals in the second quarter worth approximately $73,904,000. Orbimed Advisors LLC lifted its position in Oric Pharmaceuticals by 305.0% during the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after purchasing an additional 2,742,475 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Oric Pharmaceuticals during the fourth quarter valued at approximately $19,642,000. Siren L.L.C. grew its stake in Oric Pharmaceuticals by 197.6% in the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after buying an additional 1,990,617 shares in the last quarter. Finally, State Street Corp grew its stake in Oric Pharmaceuticals by 77.1% in the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after buying an additional 1,854,458 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.